

Winter 2021

Gene & Cell

Therapies and Vaccines

Preview

Winter 2021

Special

Publication date:
2 December, 2021

Gene & Cell Therapies **Get on Board!**

Hot topics in gene & cell therapies and vaccines

The past five years have been a critical turning point for gene and cell therapies. From the first approved oligonucleotide-based therapy to the success of CAR-T cell therapies, followed by the recent in-vivo gene therapies and the emerging gene editing strategies, these gene therapeutics and its mRNA-based vaccine counterparts are not only life-changing for patients with rare diseases, but are also laying the foundation for potential treatments of other unmet medical needs. For experts in vector engineering, analytics, preclinical development, and clinical translation to help accelerate next generation gene and cell therapy development a golden decade has broken in a time when COVID-19 vaccine manufacturing has significantly impacted the supply chains of producers of mRNA gene therapies and vector-based vaccines.

Present your expertise

CDMOs, vector providers, experts in transfection and expression vectors as well as ATMP developers will have the opportunity to present their latest products, services, and equipment in this special. EUROPEAN BIOTECHNOLOGY goes out to decision makers throughout the entire European Life Sciences sector. Take advantage of to the journal's highly relevant readership and grab this opportunity to target your audience!

Topics to be covered

Gene & Cell therapies and vaccines: vaccine vs gene & cell therapy vectors (lentiviral, AAV vectors), mRNA therapeutics/vaccines, CAR-T cell therapies, gene & cell therapy hubs, GMP-compliant process development/scale up, single use equipment vs stainless steel, media/cell line development, formulation, preclinical & clinical testing, fill & finish, process development automation, gene and cell therapies

Editorial Deadline

17-11-2021

Editorial Contact:
Thomas Gabrielczyk
Tel.: +49-1575-0977232
Fax: +49-30-264921-11
t.gabrielczyk@biocom.de

Booking Deadline

19-11-2021

Marketing Contact:
Oliver Schnell
Tel.: +49-30-264921-45
Fax: +49-30-264921-11
o.schnell@biocom.de

Publication Date

02-12-2021

Marketing Contact:
Andreas Macht
Tel.: +49-30-264921-54
Fax: +49-30-264921-11
a.macht@biocom.de

Special: Gene & Cell Therapies and Vaccines

Meet your audience!

European Biotechnology

is published in co-operation with
the following organisations:



Europe: european-biotechnology.net



Austria: biotechaustria.org



Austria: lifescienceaustria.at



Switzerland: swissbiotech.org



Spain: asebio.com



Europe: medicinesforeurope.com



Ireland: ibec.ie/ibia



Denmark: danskbiotek.dk



The Netherlands: hollandbio.nl



Germany: biodeutschland.org



Portugal: www.p-bio.org



UK: biopartner.co.uk



France: france-biotech.org



Italy: assobiotec.it



Sweden: swedenbio.com



Hungary: hungarianbiotech.org



Europe: cebr.net



Europe: ebe-biopharma.org



Norway: biotekforum.no



Finland: finbio.net



Belgium: bio.be

EUROPEAN BIOTECHNOLOGY covers the biotechnology sector of the current 27 EU member states, Norway, Switzerland, and UK. If you would like to subscribe, please refer to european-biotechnology.com.